Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tisotumab vedotin-tftv (Tivdak) is used for treating adult patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy, targeting tissue factor which is highly expressed in this type of carcinoma.
• Two studies from Randomized Controlled Trials were reviewed to gather information about the safety and effectiveness of Tivdak.
• The first study presents a combination of Tivdak with bevacizumab, pembrolizumab, or carboplatin in diverse settings for recurrent/metastatic cervical cancer. Objective Response Rate varied across treatment combinations and lines of therapy: 54.5% (1L TV + carboplatin), 40.6% (1L TV + pembrolizumab), and 35.3% (2L/3L TV + pembrolizumab).
• Adverse events such as anemia, diarrhea, nausea, and thrombocytopenia were reported but are manageable according to the same study.
• The second study focuses on single-agent efficacy of Tivdak in patients who progressed on previous treatments including doublet chemotherapy with bevacizumab if eligible; it showed an ORR of 24%, indicating considerable antitumor activity.
• Both studies enrolled adult patients with recurrent or metastatic cervical cancer, providing insights into its use across different patient subgroups and suggesting a flexible application of tisotumab vedotin-tftv in clinical management due to its favorable balance between efficacy and safety compared to existing treatments.